Clinical trial shows gene editing works for β-Thalassaemia, too

A clinical trial demonstrates that gene editing using an improved CRISPR/Cas9 system successfully treats β-Thalassaemia, a disease related to sickle-cell anemia. The therapy builds on the FDA-approved CRISPR-based treatment for sickle-cell anemia, developed through a large Chinese collaboration.